Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

ClinicalTrials.gov ID: NCT02524275

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02524275. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and Neck

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase II trial studies the side effects and how well docetaxel and capecitabine work in treating patients with squamous cell (thin, flat cells) carcinoma of the head and neck that has come back or spread to other places in the body. Drugs used in chemotherapy, such as docetaxel and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Study identification

NCT ID: NCT02524275
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: University of Nebraska; Other
Enrollment: 14 participants

Conditions and interventions

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

Drug · Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 30, 2015 (Actual)
Primary completion: Oct 28, 2021 (Actual)
Completion: Oct 28, 2021 (Actual)
Last update posted: Sep 8, 2023

2015 – 2021

United States locations

U.S. sites: 3
U.S. states: 1
U.S. cities: 2

Facility	City	State	ZIP	Site status
Faith Regional Health Services Carson Cancer Center	Norfolk	Nebraska	68701	—
Omaha Veterans Administration Medical Center	Omaha	Nebraska	68105	—
University of Nebraska Medical Center	Omaha	Nebraska	68198	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02524275, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 8, 2023 · Synced Nov 14, 2026